Camilla Fedi’s Post

View profile for Camilla Fedi, graphic

Senior Recruitment Consultant | Specializing in Medical Affairs and Clinical Development | Biotech, Pharma, and CROs | USA & Canada

Clinical Updates: #BIOSECURE Act gives drug makers until 2032 to sever ties with China. What does this mean for US Pharma? The BIOSECURE Act is a bill in the US Congress aimed at reducing reliance on Chinese biotechnology companies. It prohibits US government agencies and drug manufacturers from working with these firms, which are considered a national security risk. The latest version of the Act includes a grace period until 2032 for drugmakers to find alternative suppliers, acknowledging the challenges of an immediate switch. This could still disrupt existing supply chains and potentially lead to drug shortages or delays in research. What are tyhe possible effects? Here there is a brief summary of what this could mean for the US pharma industry: Disrupted Supply Chains: Many US drug companies rely on Chinese firms like WuXi AppTec for services like manufacturing or clinical trials. Finding new suppliers and building new partnerships will take time and resources, potentially causing delays in drug development and production. Drug Shortages: The transition period may not be smooth, leading to temporary shortages of existing medications that rely on Chinese suppliers. Increased Costs: Finding new suppliers or building in-house capabilities may be more expensive than using established Chinese firms. This could drive up drug development costs and potentially impact drug prices for consumers. Research Delays: Disruptions in ongoing research partnerships with Chinese companies could set back development timelines for new drugs and therapies. Innovation Impact: The US may lose access to some of the expertise and technologies offered by Chinese firms, potentially hindering advancements in the pharmaceutical and biotechnology sectors. https://lnkd.in/e3gvjsUd #medicalaffairs #clinicaldevelopment #medicaljobs #clinicaljobs

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs | BioSpace

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs | BioSpace

biospace.com

To view or add a comment, sign in

Explore topics